Free Trial
→ Why Some AI Stocks Already Surged Over 300 Percent (From Brownstone Research) (Ad)tc pixel
NASDAQ:MRKR

Marker Therapeutics Q3 2026 Earnings Date & Estimates

Marker Therapeutics logo
$1.04 +0.12 (+13.04%)
Closing price 04:00 PM Eastern
Extended Trading
$1.02 -0.02 (-1.83%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Marker Therapeutics is estimated to report Q3 2026 earnings on Thursday, November 12, 2026. The conference call is scheduled for November 13, 2026 at 4:00 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Conference Call Date
Conference Call
4:00 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Marker Therapeutics in Q3 2026

Marker Therapeutics is expected to post earnings of -$0.12 per share on revenue of $2.12 million. In the same quarter a year earlier Marker Therapeutics reported -$0.12 per share on revenue of $1.23 million. Marker Therapeutics last reported on August 14, 2026, posting -$0.09 per share and beating the -$0.25 consensus estimate. Marker Therapeutics has beaten the consensus EPS estimate in 6 of its last 7 quarters.

Consensus Estimates

Consensus EPS
-$0.12
Expected Revenue
$2.12 million
Prior-Year EPS
-$0.12
Prior-Year Revenue
$1.23 million
Expected Revenue Growth
+71.5%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.09 (Beat by +$0.16)
EPS Beat Rate
6 of last 7 quarters

Prepare for the Q3 2026 Call

Marker Therapeutics Q3 2026 Earnings FAQ

Marker Therapeutics (NASDAQ:MRKR) is estimated to report Q3 2026 earnings on Thursday, November 12, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

Marker Therapeutics' Q3 2026 earnings conference call is scheduled for Friday, November 13, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Marker Therapeutics to post earnings of -$0.12 per share for Q3 2026.

The consensus revenue estimate for Marker Therapeutics is $2.12 million for Q3 2026.

Marker Therapeutics Earnings Headlines

Head-To-Head Survey: Molecular Partners (NASDAQ:MOLN) & Marker Therapeutics (NASDAQ:MRKR)
October 13 at 4:45 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31114208
Head-To-Head Review: Marker Therapeutics (NASDAQ:MRKR) vs. Longeveron (NASDAQ:LGVN)
October 12, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31109868
I'm giving you a space stock today. Free.
On December 8th, $600 billion in frozen SpaceX stock comes loose. Dylan Jovine says one simple purchase in any regular brokerage account gives investors exposure to SpaceX and 66 of its neighbors, without an IPO allocation. He is also naming two space stocks he would consider dumping before December, plus a $14 stock that Elon has personally put his name on.tc pixel
October 16 at 1:00 AM  |  Behind the Markets (Ad)
Marker Highlights Expanded Manufacturing Support For MT-601
September 22, 2026  |  rttnews.comhttps://www.rttnews.com/3692987/marker-highlights-expanded-manufacturing-support-for-mt-601.aspx
Marker Therapeutics Highlights Expanded Manufacturing Support of CDMO Partner Following Formation of Kincellis Advanced Therapies
September 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/22/3366273/0/en/marker-therapeutics-highlights-expanded-manufacturing-support-of-cdmo-partner-following-formation-of-kincellis-advanced-therapies.html
Analysts Offer Insights on Healthcare Companies: Marker Therapeutics (MRKR) and CSPC Pharmaceutical Group (OtherCHJTF)
August 22, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/MRKR/pressreleases/3969567/analysts-offer-insights-on-healthcare-companies-marker-therapeutics-mrkr-and-cspc-pharmaceutical-group-otherchjtf/
See More Marker Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Marker Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Marker Therapeutics and other key companies, straight to your email.

About Marker Therapeutics

Marker Therapeutics (NASDAQ:MRKR) is a clinical-stage biotechnology company focused on developing T-cell therapies for cancer. The company’s approach uses tumor-specific T cells designed to recognize multiple tumor-associated antigens, with the goal of addressing the heterogeneity of solid tumors and potentially reducing the likelihood of treatment resistance.

Marker’s lead program is MT-601, an autologous multi-antigen-specific T-cell therapy being evaluated for pancreatic ductal adenocarcinoma. The company’s technology has historically targeted several cancer-associated antigens, including WT1, PRAME, survivin, NY-ESO-1 and MAGE-A4. Marker has also investigated related T-cell programs for other malignancies, including acute myeloid leukemia.

The company was created through the combination of TapImmune and Marker Therapeutics and is headquartered in Houston, Texas. Marker remains focused primarily on research and clinical development rather than commercial product sales, with its activities centered on advancing cell-based immunotherapies through clinical testing, principally in the United States.

View Marker Therapeutics Profile
Earnings Tools